The calcium ‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
In conclusion, exposure to luminal neratinib resulted in a pronounced elevation in fluid secretion in the rat intestine. Increasing luminal calcium inhibits the neratinib‐associated fluid secretion in a dose‐dependent manner. These results suggest that CaSR activation may be a potent therapeutic target to reduce chemotherapy‐associated diarrhea.
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Taras Lysyy,
Alshad S. Lalani,
Elizabeth A. Olek,
Irmina Diala,
John P. Geibel Tags: ORIGINAL ARTICLE Source Type: research
More News: Breast Cancer | Calcium | Cancer | Cancer & Oncology | Cancer Therapy | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Oral Cancer | Study